HK1217289A1 - 使用細菌治療癌症的組合物和方法 - Google Patents

使用細菌治療癌症的組合物和方法

Info

Publication number
HK1217289A1
HK1217289A1 HK16105240.9A HK16105240A HK1217289A1 HK 1217289 A1 HK1217289 A1 HK 1217289A1 HK 16105240 A HK16105240 A HK 16105240A HK 1217289 A1 HK1217289 A1 HK 1217289A1
Authority
HK
Hong Kong
Prior art keywords
bacteria
cancer
compositions
treatment
methods
Prior art date
Application number
HK16105240.9A
Other languages
English (en)
Inventor
Michael J Newman
Original Assignee
Decoy Biosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decoy Biosystems Inc filed Critical Decoy Biosystems Inc
Publication of HK1217289A1 publication Critical patent/HK1217289A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK16105240.9A 2013-01-02 2016-05-09 使用細菌治療癌症的組合物和方法 HK1217289A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361748369P 2013-01-02 2013-01-02
PCT/US2013/077441 WO2014107365A1 (en) 2013-01-02 2013-12-23 Compositions and methods for treatment of cancer using bacteria

Publications (1)

Publication Number Publication Date
HK1217289A1 true HK1217289A1 (zh) 2017-01-06

Family

ID=49943600

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16105240.9A HK1217289A1 (zh) 2013-01-02 2016-05-09 使用細菌治療癌症的組合物和方法

Country Status (17)

Country Link
US (5) US10195259B2 (zh)
EP (1) EP2941258B1 (zh)
JP (1) JP6125041B2 (zh)
KR (1) KR102214794B1 (zh)
CN (1) CN104884073B (zh)
AU (1) AU2013371454B2 (zh)
CA (1) CA2896858C (zh)
DK (1) DK2941258T3 (zh)
EA (1) EA030573B1 (zh)
ES (1) ES2759854T3 (zh)
HK (1) HK1217289A1 (zh)
IL (1) IL239453B (zh)
MX (1) MX368210B (zh)
PL (1) PL2941258T3 (zh)
PT (1) PT2941258T (zh)
TW (1) TWI664976B (zh)
WO (1) WO2014107365A1 (zh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2941258T3 (da) * 2013-01-02 2019-12-16 Decoy Biosystems Inc Sammensætninger og fremgangsmåder til behandling af cancer ved anvendelse af bakterier
WO2015153820A1 (en) * 2014-04-02 2015-10-08 Felder Mitchell S Ctla-4 blockade with metronomic chemotherapy for the treatment of cancer
RU2731098C2 (ru) * 2014-08-19 2020-08-28 Нэшнл Юниверсити Корпорейшн Окаяма Юниверсити Способ улучшения функции иммунных клеток и оценки мультифункциональности иммунных клеток
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US20200282037A1 (en) * 2017-06-16 2020-09-10 Nantbio, Inc. Bacterial vaccine
WO2019014398A1 (en) 2017-07-11 2019-01-17 Actym Therapeutics, Inc. MODIFIED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF
WO2019099121A1 (en) * 2017-11-20 2019-05-23 Synthetic Genomics, Inc. Vibrio sp. organisms with modified lipopolysaccharide
CN111902153A (zh) * 2018-01-19 2020-11-06 4D制药研究有限公司 用于治疗或预防癌症的组合疗法
JP7340591B2 (ja) 2018-07-11 2023-09-07 アクティム・セラピューティクス・インコーポレイテッド 遺伝子操作された免疫刺激性細菌菌株およびその使用
US11242528B2 (en) 2018-08-28 2022-02-08 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
MX2021003551A (es) * 2018-09-27 2021-08-16 Decoy Biosystems Inc Metodos de tratamiento de infecciones utilizando bacterias.
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
WO2020232389A1 (en) * 2019-05-16 2020-11-19 City Of Hope Compositions and methods for targeting tumor-associated extracellular matrix components to improve drug delivery
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
JP2023548417A (ja) * 2020-11-09 2023-11-16 インダストリー、ファウンデーション、オブ、チョンナム、ナショナル、ユニバーシティ 癌の予防および治療用サルモネラ菌株およびその用途
FI129784B (en) * 2021-04-27 2022-08-31 Solar Foods Oy METHODS OF PRODUCING MICROPRODUCTS
WO2024107543A1 (en) * 2022-11-17 2024-05-23 Indaptus Therapeutics, Inc. Treatment of cancers and infectious diseases with killed intact bacteria

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4842855A (en) * 1980-12-19 1989-06-27 University Of Pittsburgh Antitumor process using a Brucella abortus preparation
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US5171738A (en) * 1982-10-04 1992-12-15 Toray Industries, Inc. Method of treating malignant tumors
JPH04270965A (ja) 1990-05-18 1992-09-28 Burton W Blais オリゴペプタイド吸着担体の調製方法、及びこれを使用したリポ多糖類の検定と除去方法
US6264952B1 (en) 1993-11-05 2001-07-24 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for protecting a mammalian host against infection by Brucella
WO1996030043A1 (en) 1995-03-24 1996-10-03 Ophidian Pharmaceuticals Treatment for verotoxin-producing escherichia coli
US6190657B1 (en) 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5997881A (en) * 1995-11-22 1999-12-07 University Of Maryland, Baltimore Method of making non-pyrogenic lipopolysaccharide or A
WO1998053851A1 (en) * 1997-05-28 1998-12-03 University Of Iowa Research Foundation Laft mutants of pathogenic gram-negative bacteria
EP1012232B1 (en) 1997-09-10 2009-10-28 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
WO2001024637A1 (en) * 1999-10-04 2001-04-12 Vion Pharmaceuticals, Inc. Methods for treating solid tumors with irradiation and bacteria
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
WO2001025397A2 (en) * 1999-10-04 2001-04-12 Vion Pharmaceuticals, Inc. Compositions and methods for tumor-targeted delivery of effector molecules
DE60137334D1 (de) * 2000-06-09 2009-02-26 Baylor College Medicine Kombination von antimikrobiellen wirkstoffen und bakterieller interferenz zum überziehen medizinischer vorrichtungen
ES2431090T3 (es) 2001-11-21 2013-11-25 The Johns Hopkins University Terapia bacteriolítica de combinación para el tratamiento de tumores
WO2003063593A1 (en) 2002-01-28 2003-08-07 Vion Pharmaceuticals, Inc. Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent
DE602004025834D1 (de) 2003-10-22 2010-04-15 Univ Johns Hopkins Die behandlung von tumoren
US8034359B2 (en) 2004-06-07 2011-10-11 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to cancers
AU2005251397B2 (en) * 2004-06-07 2010-11-11 Qu Biologics Inc. Bacterial compositions for the treatment of cancer
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US8822194B2 (en) 2004-06-29 2014-09-02 Anticancer, Inc. Cancer selective auxotrophs
EP1984021B1 (en) 2006-01-19 2016-08-10 Research Corporation Technologies, Inc Viable non-toxic gram negative bacteria
DK2545162T3 (en) 2010-03-12 2017-02-06 Res Corp Tech Viable Gram Negative Bacteria Lacking Outer MEMBRANE AGONISTS FOR TLR4 / MD-2
DK2941258T3 (da) 2013-01-02 2019-12-16 Decoy Biosystems Inc Sammensætninger og fremgangsmåder til behandling af cancer ved anvendelse af bakterier

Also Published As

Publication number Publication date
CN104884073B (zh) 2019-07-12
TWI664976B (zh) 2019-07-11
DK2941258T3 (da) 2019-12-16
AU2013371454A1 (en) 2015-07-02
CA2896858C (en) 2022-08-23
EP2941258B1 (en) 2019-09-11
JP6125041B2 (ja) 2017-05-10
EA030573B1 (ru) 2018-08-31
CN104884073A (zh) 2015-09-02
US10052371B2 (en) 2018-08-21
CA2896858A1 (en) 2014-07-10
US20160199422A1 (en) 2016-07-14
JP2016505604A (ja) 2016-02-25
US10195259B2 (en) 2019-02-05
MX368210B (es) 2019-09-24
PL2941258T3 (pl) 2020-02-28
TW201440779A (zh) 2014-11-01
IL239453A0 (en) 2015-07-30
US11045504B2 (en) 2021-06-29
EP2941258A1 (en) 2015-11-11
IL239453B (en) 2020-03-31
US9265804B2 (en) 2016-02-23
KR102214794B1 (ko) 2021-02-10
WO2014107365A1 (en) 2014-07-10
US20190307869A1 (en) 2019-10-10
PT2941258T (pt) 2019-12-12
US20160228523A1 (en) 2016-08-11
EA201591017A1 (ru) 2015-12-30
ES2759854T3 (es) 2020-05-12
MX2015008606A (es) 2016-01-14
KR20150102093A (ko) 2015-09-04
US20220047649A1 (en) 2022-02-17
US20140212396A1 (en) 2014-07-31
BR112015015832A2 (pt) 2017-07-11
AU2013371454B2 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
HK1217289A1 (zh) 使用細菌治療癌症的組合物和方法
IL273090B (en) Methods and preparations for the treatment of cancer
IL245281A0 (en) Methods and preparations for the treatment of cancer
GB201320723D0 (en) Composition and methods of treatment
EP2958936A4 (en) METHOD AND COMPOSITIONS FOR TREATING CORI DISEASE
HK1200739A1 (zh) 用於治療癌症的診斷方法和組合物
IL238177A0 (en) Methods and preparations for the treatment of cancer
EP3004396A4 (en) Methods and compositions for the treatment of cancer
HK1220374A1 (zh) 用於治療碳氧血紅蛋白血症的組合物和方法
PL3082845T3 (pl) Sposoby i kompozycje do leczenia neuropatii obwodowych
SG10201710538XA (en) Compositions and methods for treating skin
EP2958591A4 (en) METHODS AND COMPOSITIONS RELATED TO THE TREATMENT OF CANCER
EP2928456A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
GB201403083D0 (en) Treatment of cancer
HK1217715A1 (zh) 治療中風的組合物及方法
HK1232118A1 (zh) 癌症的治療
EP2971044A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
AU2013902004A0 (en) Compositions for Therapy and Methods of Treatment
GB201322347D0 (en) Treatment of cancer
GB201318742D0 (en) Treatment of cancer
GB201308529D0 (en) Treatment of cancer
GB201322346D0 (en) Combination treatment of cancer
GB201305020D0 (en) Treatment of cancer